Pfizer: JAK Inhibitors for the Treatment of Patients With Rheumatoid Arthritis (RA): Learnings from Real World Experience


Valkenburg
English
Satellite Symposium
04 June 2020 17:30 - 18:30

EULAR sincerely apologises for the technical problems experienced during the Pfizer live satellite symposium “JAK Inhibitors for the Treatment of Patients With Rheumatoid Arthritis (RA): Learnings from Real World Experience”.

The session has now been updated with a clean version.

 

Highlight the importance of real-world data as part of the totality of evidence for medical therapies  

  • Explore the available real-world evidence for JAK inhibitors in the management of patients with RA  


The Value of Real-World Data

  • Describe the need for real-world data and how they add to data collected from clinical trials
  • Explore different real-world data sources, and their relative strengths and limitations 


Effectiveness and Persistence of JAK Inhibitors in Patients With RA Treated in the Real World

  • Highlight the use of effectiveness and persistence data in real-world studies to support evolving patient needs in patients with RA


Safety of JAK Inhibitors in the Real World in Patients With RA

  • Discuss the evidence for the safety profile of JAK inhibitors in real-world studies in patients with RA, and the implication on treatment strategies



Presentations

Title Time Add to calendar
Pfizer Symposium (Live)
04 June 2020 17:30 - 17:30 Add to calendar
Welcome and Faculty Introductions
04 June 2020 17:30 - 17:35 Add to calendar
The Value of Real-World Data
04 June 2020 17:35 - 17:45 Add to calendar
Effectiveness and Persistence of JAK Inhibitors in Patients With RA Treated in the Real World
04 June 2020 17:45 - 17:55 Add to calendar
Safety of JAK Inhibitors in the Real World in Patients With RA
04 June 2020 17:55 - 18:10 Add to calendar
Faculty Discussion
04 June 2020 18:10 - 18:25 Add to calendar
Summary and Close
04 June 2020 18:25 - 18:30 Add to calendar